Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Clover Biopharmaceuticals Ltd. ( (HK:2197) ).
Clover Biopharmaceuticals Ltd. announced that it has received an arbitration request from Gavi, seeking repayment of $224 million in advance payment amounts. Clover believes the claim is without merit and intends to defend itself vigorously, while continuing its development of the RSV vaccine candidate SCB-1019.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on the development of vaccines. The company is advancing its proprietary RSV vaccine candidate SCB-1019 for use in RSV re-vaccination settings and as part of a respiratory combination vaccine.
Average Trading Volume: 1,363,709
Technical Sentiment Signal: Hold
Current Market Cap: HK$319.1M
See more insights into 2197 stock on TipRanks’ Stock Analysis page.